Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Platinum-refractory SCCHN
NCT05802290Phase 3Completed
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Nov 2017
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Gruppo Oncologico Nord Ovest. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT05802290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05802290.